Recurrent Salivary Gland Carcinoma Active Not Recruiting Phase 1 / 2 Trials for Vorinostat (DB02546)
Indication | Status | Phase |
---|---|---|
DBCOND0037143 (Recurrent Salivary Gland Carcinoma) | Active Not Recruiting | 1 / 2 |
clinicaltrials.gov Identifier | Title | Purpose | Drugs |
---|---|---|---|
NCT02538510 | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | Treatment |